

Testosterone's Role in Cardiovascular Health: A Review of the Literature

by Gary Huber, DO, AOBEM, and Andrew Comb, RPh

References

1. Morris, Wooding, Grant. The answer is 17 years, what is the question: understanding time lags in translational research. *J R Soc Med.* 2011; 104: 510–520.
2. Basaria S, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. *JAMA.* 2015;314(6): 570-581.
3. Chang KJ, et al. Influences of percutaneous administration of estradiol and progesterone on human breast epithelial cell cycle in vivo. *Fertility and Sterility.* 1995;63(4):785-791.
4. Du, Sanchez K, et al. Percutaneous progesterone delivery via cream or gel application in postmenopausal women: a randomized cross-over study of progesterone levels in serum, whole blood, saliva, and capillary blood. *Menopause: The Journal of The North American Menopause Society.* 2013; 20 (11).
5. Zhao SP, Li XP. The association of low plasma testosterone level with coronary artery disease in Chinese men. *Int J Cardiol.* 1998;63:161.
6. Simon D, et al. Association between plasma total testosterone and cardiovascular risk factors in healthy adult men: the Telecom Study. *J Clin Endocrinol Metab.* 1997;82:682.
7. English KM, et al. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. *Eur Heart J.* 2000;21:890.
8. Gluud, C. Testosterone treatment of men with alcoholic cirrhosis: A double-blind study. *Hepatology.* 1986; 6(5), 807-813.
9. Xu L, et al. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. *BMC Med.* 2013;11:108.
10. Vigen R, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. *JAMA.* 2013; 310: 1829–36.
11. Corona G, et al. Testosterone replacement therapy and cardiovascular risk: a review. *World J Men's Health.* 2015; 33(3):130-142.
12. Calof OM, et al. Adverse events associated with testosterone replacement in middle-aged and older men: a meta- analysis of randomized, placebo-controlled trials. *J Gerontol A Biol Sci Med Sci.* 2005;60:1451-7.
13. Haddad RM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. *Mayo Clin Proc.* 2007;82:29-39.
14. Fernández-Balsells MM, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. *J Clin Endocrinol Metab.* 2010;95:2560-75.
15. Corona G, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-analysis. *Expert Opin Drug Saf.* 2014;13:1327-51.
16. English KM, et al. Low-dose transdermal testosterone therapy improves angina threshold in men with chronic stable angina: a randomized, double-blind, placebo-controlled study. *Circulation.* 2000; 102: 1906–11.
17. Malkin CJ, et al. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. *Eur Heart J.* 2006; 27: 57–64.
18. Caminiti G, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. *J Am Coll Cardiol.* 2009; 54: 919–27.
19. Shores MM, et al. Testosterone treatment and mortality in men with low testosterone levels. *J Clin Endocrinol Metab.* 2012;97:2050–8.
20. Muraleedharan V, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. *Eur J Endocrinol.* 2013; 169: 725–33.
21. Cai X, et al. Metabolic effects of testosterone replacement therapy on hypogonadal men with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. *Asian J of Andrology.* 2014;16(1): 146.
22. Haider A, et al. Men with testosterone deficiency and a history of cardiovascular diseases benefit from long-term testosterone therapy: observational, real-life data from a registry study. *Vascular Health and Risk Management.* 2016;12: 251.
23. Esterbauer H, Wag G, Puhl H. Lipid peroxidation and its role in atherosclerosis. *Br Med Bull.* 1993;49:566.
24. Kodama T, et al. Type I macrophage scavenger receptor contains alpha-helical and collagen-like coiled coils. *Nature.* 1990;343:531.
25. Witztum JL. Immunological response to oxidized LDL. *Atherosclerosis.* 1997;131:S9.
26. Lopes-Virella MF, et al. The uptake of LDL-IC by human macrophages: predominant involvement of the Fc gamma RI receptor. *Atherosclerosis.* 1997;135:161.
27. Puurunen M, et al. Anibody against oxidized low-density lipoprotein predicting myocardial infarction. *Arch Intern Med.* 1994;154:2605.
28. Barud W, et al. Inverse relationship between total testosterone and anti-oxidized low density lipoprotein antibody levels in ageing males. *Atherosclerosis.* 2002;164 (2):283-288.